MIAMI , July 25, 2024 /PRNewswire/ -- NAVIGANTIS Inc. announced today that it has closed a $12 million Series A financing led by Puma Venture Capital, with participation from Cormorant Asset Management and Mirae Asset Capital. All existing NAVIGANTIS investors participated in the financing round.
Amit Hazan , Founder and Managing Partner at Puma Venture Capital will join NAVIGANTIS Board of Directors. Proceeds from the financing will be used to support the ongoing development and testing of the VASCO robot to bring it into first-in-human clinical trials in neurovascular procedures. We are thrilled and fortunate to have the support of such esteemed partner investors who share our vision for revolutionizing neurovascular care with robotics," said Mor Dayan, CEO of NAVIGANTIS.
Neurovascular diseases, including stroke, aneurysms, and Arteriovenous malformations (AVMs) are leading causes of death and disability worldwide. In the case of stroke, it affects someone in the US every 40 seconds, and is the leading cause of disability. Despite improvements in stroke systems of care, many Americans still lack timely access to acute stroke intervention.
Mechanical Thrombectomy (MT) is now the gold standard for acute ischemic stroke. If a patient receives MT within 2 hours from symptoms onset it has a 90% chance of re-achieving independence, at 6 hours the number drops to 30%. These numbers reaffirm the importance to ensure the procedure is timely and widely available, which is currently c.